Physician profile
John Ferullo
NPI 1528056439
$3,800.29
in general payments reported to CMS, 2019-2025
23 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,474 · 2020: $597 · 2021: $111 · 2022: $61.02 · 2023: $490 · 2024: $765 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $467.17 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.23 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $395.41 | 2019-2025 | Farxiga |
| Pfizer INC. | $291.53 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $271.04 | 2023-2025 | Onpattro, Amvuttra |
| Medtronic Vascular, INC. | $234.71 | 2019-2020 | |
| Bardy Diagnostics, INC. | $225.00 | 2020 | |
| Scpharmaceuticals INC. | $188.15 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $180.42 | 2019-2020 | |
| Amgen INC. | $174.03 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $136.80 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $130.71 | 2019-2024 | Xarelto |
| Lantheus Medical Imaging, INC. | $108.61 | 2019-2020 | |
| Boston Scientific Corporation | $107.12 | 2020-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $83.82 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $75.61 | 2019 | |
| Vifor Pharma, INC. | $64.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.55 | 2019 | |
| Heartflow, INC. | $56.03 | 2024-2025 | |
| Esperion Therapeutics, INC. | $33.51 | 2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $25.67 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $20.09 | 2024 | Opsumit |
| Lilly USA, LLC | $17.64 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ferullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.